More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$745468612
EPS
-0.64
P/E ratio
--
Price to sales
3.41
Dividend yield
--
Beta
1.150317
Previous close
$5.63
Today's open
$5.64
Day's range
$5.47 - $5.74
52 week range
$3.31 - $6.34
show more
CEO
Wenbin Jiang
Employees
682
Headquarters
Fremont, CA
Exchange
Nasdaq Global Select
Shares outstanding
130783967
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Cytek Biosciences, Inc. (CTKB) Q3 2026 Earnings Call Transcript
Cytek Biosciences, Inc. (CTKB) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

Cytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the Year
FREMONT, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that its Cytek Aurora ® Evo system has been named Drug Discovery Innovation of the Year in the 2026 BioTech Breakthrough Awards.
GlobeNewsWire • Nov 5, 2026

Cytek Biosciences Q3 Earnings Call Highlights
Cytek Biosciences NASDAQ: CTKB reported third-quarter 2026 revenue of $53.2 million, up 2% from a year earlier, as growth in the U.S. and demand for its high-end instruments helped offset weakness in Asia-Pacific.
MarketBeat • Nov 4, 2026

Cytek Biosciences Reports Third Quarter 2026 Financial Results
FREMONT, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2026.
GlobeNewsWire • Nov 4, 2026

Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.01 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Cytek Biosciences to Participate in Upcoming Investor Conferences
FREMONT, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences:
GlobeNewsWire • Oct 29, 2026

Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
Cytek Biosciences (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 28, 2026

Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
FREMONT, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026. The company's management will also host a conference call to discuss its results, business developments and outlook beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day.
GlobeNewsWire • Oct 21, 2026

Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
Cytek has expanded its Cytek® Cloud digital ecosystem with a new Cloud Analysis tool to create the industry's first end-to-end flow cytometry platform.
GlobeNewsWire • Sep 23, 2026

Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
Investors need to pay close attention to CTKB stock based on the movements in the options market lately.
Zacks Investment Research • Sep 17, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Cytek Biosciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.